S Toma

Summary

Affiliation: University of Genoa
Country: Italy

Publications

  1. ncbi Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG)
    S Toma
    Department of Medical Oncology, University of Genoa National Institute for Cancer Research, Italy
    Anticancer Res 20:485-91. 2000
  2. ncbi Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients
    S Toma
    Department of Oncology, Biology and Genetics, National Institute for Cancer Research, 16132 Genova, Italy
    Int J Oncol 17:991-1000. 2000
  3. ncbi RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines
    S Toma
    National Institute for Cancer Research, Department of Clinical and Experimental Oncology, University of Genoa, Italy
    Int J Cancer 78:86-94. 1998
  4. ncbi Retinoids in lung cancer chemoprevention and treatment
    S Toma
    Department of Medical Oncology, University of Genova, Italy
    Ann Oncol 10:S95-102. 1999
  5. ncbi Chemoprevention of tumors: the role of RAR-beta
    S Toma
    Department of Oncology, Biology and Genetics, University of Genoa, Italy
    Int J Biol Markers 18:78-81. 2003
  6. ncbi Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review)
    S Toma
    Department of Medical Oncology, University of Genoa, National Institute for Cancer Research, 16132 Genova, Italy
    Int J Oncol 15:321-37. 1999

Collaborators

Detail Information

Publications6

  1. ncbi Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG)
    S Toma
    Department of Medical Oncology, University of Genoa National Institute for Cancer Research, Italy
    Anticancer Res 20:485-91. 2000
    ..Few clinical trials in adult STS have been published until now, with disappointing and often contrasting results...
  2. ncbi Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients
    S Toma
    Department of Oncology, Biology and Genetics, National Institute for Cancer Research, 16132 Genova, Italy
    Int J Oncol 17:991-1000. 2000
    ..Neither the ATRA + tamoxifen nor the ATRA + tamoxifen + interferon combinations potentiated the ATRA-induced biological changes. Future studies evaluating the role of RAR-beta as a biological marker of retinoid activity are warranted...
  3. ncbi RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines
    S Toma
    National Institute for Cancer Research, Department of Clinical and Experimental Oncology, University of Genoa, Italy
    Int J Cancer 78:86-94. 1998
    ..This retinoid antagonist seems to be a compound that exerts an anti-tumor activity but does not induce the toxic side effects of retinoids and might, therefore, be considered as a candidate for cancer therapy...
  4. ncbi Retinoids in lung cancer chemoprevention and treatment
    S Toma
    Department of Medical Oncology, University of Genova, Italy
    Ann Oncol 10:S95-102. 1999
    ..Such selective molecules may have a greater activity against lung cancer, with a more favourable toxicity profile, as recently suggested by our preliminary data on Ro 41-5253...
  5. ncbi Chemoprevention of tumors: the role of RAR-beta
    S Toma
    Department of Oncology, Biology and Genetics, University of Genoa, Italy
    Int J Biol Markers 18:78-81. 2003
    ..Transitions between successive stages can be enhanced or inhibited in the laboratory by different types of agents, such activities providing the fundamental basis for chemoprevention...
  6. ncbi Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review)
    S Toma
    Department of Medical Oncology, University of Genoa, National Institute for Cancer Research, 16132 Genova, Italy
    Int J Oncol 15:321-37. 1999
    ..To this end, clinical research should incorporate biological studies to allow the selection of subgroups of patients who are most likely to benefit from TAM-based treatment...